Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: THC stock price vs WAT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WAT's multiple
Needs WAT P/E.
Implied fair value · at THC's multiple
Needs THC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TENET HEALTHCARE CORP · implied price per share
Bear
$105.38
Base
$143.97
Bull
$194.22
Waters Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HCA Healthcare, Inc.
THC vs HCA
UNIVERSAL HEALTH SERVICES INC
THC vs UHS
COMMUNITY HEALTH SYSTEMS INC
THC vs CYH
Encompass Health Corp
THC vs EHC
SELECT MEDICAL HOLDINGS CORP
THC vs SEM
Acadia Healthcare Company, Inc.
THC vs ACHC
DANAHER CORP /DE/
THC vs DHR
AGILENT TECHNOLOGIES, INC.
THC vs A
BIO-RAD LABORATORIES, INC.
THC vs BIO
THERMO FISHER SCIENTIFIC INC.
THC vs TMO
BRUKER CORP
THC vs BRKR
BIO-TECHNE Corp
THC vs TECH
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe THC can sustain its current profitability while improving growth and keeping leverage stable, then a measured long position makes sense because the stock trades at a major discount to WAT and sits below the P/E-derived implied value; otherwise, the premium-quality profile of WAT justifies caution on expecting the full valuation gap to close.
THC trades at a steep discount to WAT on both earnings and sales-based valuation, but that discount is partly explained by lower growth and lower margin quality. The model’s implied P/E price of $543.17 suggests substantial upside, yet WAT-implied range is much wider than the historical and DCF ranges, highlighting that comparables are stretching the valuation.
Supporting Metrics
